<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04428944</url>
  </required_header>
  <id_info>
    <org_study_id>MP-33-2021-2805</org_study_id>
    <nct_id>NCT04428944</nct_id>
  </id_info>
  <brief_title>STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation</brief_title>
  <acronym>STARAF3</acronym>
  <official_title>Strategies for Catheter Ablation of Persistent Atrial Fibrillation: a Randomized, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy of three different ablation strategies&#xD;
      in patients with persistent AF:&#xD;
&#xD;
        1. PV antral isolation alone (PVAI)&#xD;
&#xD;
        2. PV antral isolation plus ablation of drivers (PVAI+drivers)&#xD;
&#xD;
        3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies&#xD;
           will employ contemporary catheter ablation technology using more efficient open&#xD;
           irrigated tip cooling and contact force sensing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from documented atrial arrhythmia ≥ 30 seconds at 18 months after one ablation procedure on or off antiarrhythmic medications (AAM).</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF &gt; 30 seconds at 18 months after one procedure on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF &gt; 30 seconds at 18 months after one or more procedures on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented atrial arrhythmia &gt; 30 seconds at 18 months after one or more procedures on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF &gt; 30 seconds at 18 months after one procedure off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented atrial arrhythmia &gt; 30 seconds at 18 months after one procedure off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF &gt; 30 seconds at 18 months after one or more procedures off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented atrial arrhythmia &gt; 30 seconds after one or more procedures off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented symptomatic AF &gt; 30 seconds at 18 months after one procedure on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented symptomatic atrial arrhythmia &gt; 30 seconds after one procedure on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each of the above success measures stratified by CHA2DS2-VASc score</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri-procedural complications including stroke, PV stenosis, cardiac perforation, esophageal injury, phrenic nerve palsy, and death</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time (dose)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiofrequency time</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of repeat procedures</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of each strategy on AF cycle length changes and AF termination</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of acute AF termination on long-term procedural outcome</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurements during follow-up using AFEQT questionnaire</measure>
    <time_frame>6-12-18 months</time_frame>
    <description>AFEQT questionnaires will be used at baseline, 6, 12 and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurements during follow-up using SF36 questionnaires</measure>
    <time_frame>6-12-18 months</time_frame>
    <description>SF36 questionnaires will be used at baseline, 6, 12 and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AF burden post-ablation procedure (% of time in AF)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PV antral isolation alone (PVAI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PV antral isolation alone (PVAI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PV antral isolation plus ablation of drivers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PV antral isolation plus ablation of drivers (PVAI+drivers)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PV antral isolation plus isolation of posterior wall</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PV antral isolation plus isolation of LA posterior wall (PVAI+Box)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)</intervention_name>
    <description>Standard PVI</description>
    <arm_group_label>PV antral isolation alone (PVAI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)</intervention_name>
    <description>Standard PVI + Ablation of drivers in LA and RA</description>
    <arm_group_label>PV antral isolation plus ablation of drivers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)</intervention_name>
    <description>Standard PVI + Electrical isolation of the posterior wall of the left atrium</description>
    <arm_group_label>PV antral isolation plus isolation of posterior wall</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 years of age or older&#xD;
&#xD;
          2. Patients undergoing first-time ablation procedure for AF&#xD;
&#xD;
          3. Patients with persistent AF defined as a sustained episode more than 3 months but less&#xD;
             than three years&#xD;
&#xD;
          4. Patients with symptomatic AF - symptomatic patients are those who have been aware of&#xD;
             their AF at any time within the last 5 years prior to enrolment. Symptoms may include,&#xD;
             but are not restricted to, palpitations, shortness of breath, chest pain, fatigue,&#xD;
             left ventricular dysfunction, or other symptoms or any combination of the above&#xD;
&#xD;
          5. Patients whose AF has been refractory to at least one antiarrhythmic drug&#xD;
&#xD;
          6. At least one episode of AF must have been documented by ECG, holter, loop recorder,&#xD;
             telemetry, trans-telephonic monitor or implanted device within the last 2 years from&#xD;
             enrolment&#xD;
&#xD;
          7. Patients must be able and willing to provide written informed consent to participate&#xD;
             in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with paroxysmal AF (no episodes lasting &gt; 7 days)&#xD;
&#xD;
          2. Patients with early persistent AF, sustained episode ≤ 3 months&#xD;
&#xD;
          3. Patients with very long lasting persistent AF (episodes lasting &gt; 3 years)&#xD;
&#xD;
          4. Patients with CHA2DS2-VASc score of 0.&#xD;
&#xD;
          5. Patients for whom cardioversion or sinus rhythm will never be attempted/pursued&#xD;
&#xD;
          6. Patients with AF felt to be secondary to an obvious reversible cause&#xD;
&#xD;
          7. Patients with contraindication to oral anticoagulation or systemic anticoagulation&#xD;
             with heparin&#xD;
&#xD;
          8. Patients with left atrial diameter &gt; 60 mm in the parasternal long axis view&#xD;
&#xD;
          9. Patients who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Verma, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Macle, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Morello</last_name>
    <phone>514-376-3330</phone>
    <phone_ext>6279</phone_ext>
    <email>mary.morello@icm-mhi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Adelaide Hospital and Cardiovascular Centre</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prashanthan Sanders, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz,</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Scherr, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Pürerfellner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLV Hospital Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom De Potter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital (UZA)</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Sarkozy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary Foothills</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Morillo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver,</city>
        <state>British Colombia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Andrade, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, Vancouver, BC</name>
      <address>
        <city>Vancouver</city>
        <state>British Colombia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Deyell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Jubilee Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Colombia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Novak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Amit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Center</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mouhannad Sadek, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laurent Macle</name>
      <address>
        <city>Montreal</city>
        <state>QC - Québec</state>
        <zip>H1T 1c8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Macle, MD</last_name>
      <phone>5143763330</phone>
    </contact>
    <contact_backup>
      <last_name>Mary Morello</last_name>
      <phone>5143763330</phone>
      <phone_ext>6279</phone_ext>
      <email>mary.morello@icm-mhi.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MUHC, McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidal Essebag, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Champagne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Fleurimont, CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Roux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital St-Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc Pasquié, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Sebag, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul Albenque, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Tonkin</name>
      <address>
        <city>Villeurbanne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril Durand, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>February 13, 2023</last_update_submitted>
  <last_update_submitted_qc>February 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Atul Verma</investigator_full_name>
    <investigator_title>Cardiologist electrophysiologist</investigator_title>
  </responsible_party>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04428944
org study id: MP-33-2021-2805
nct id: NCT04428944
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The objective of this study is to compare the efficacy of three different ablation strategies
      in patients with persistent AF:

        1. PV antral isolation alone (PVAI)

        2. PV antral isolation plus ablation of drivers (PVAI+drivers)

        3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies
           will employ contemporary catheter ablation technology using more efficient open
           irrigated tip cooling and contact force sensing.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Freedom from documented atrial arrhythmia ≥ 30 seconds at 18 months after one ablation procedure on or off antiarrhythmic medications (AAM).
time frame: 18 months
measure: Freedom from documented AF > 30 seconds at 18 months after one procedure on or off AAM
time frame: 18 months
measure: Freedom from documented AF > 30 seconds at 18 months after one or more procedures on or off AAM
time frame: 18 months
measure: Freedom from documented atrial arrhythmia > 30 seconds at 18 months after one or more procedures on or off AAM
time frame: 18 months
measure: Freedom from documented AF > 30 seconds at 18 months after one procedure off AAM
time frame: 18 months
measure: Freedom from documented atrial arrhythmia > 30 seconds at 18 months after one procedure off AAM
time frame: 18 months
measure: Freedom from documented AF > 30 seconds at 18 months after one or more procedures off AAM
time frame: 18 months
measure: Freedom from documented atrial arrhythmia > 30 seconds after one or more procedures off AAM
time frame: 18 months
measure: Freedom from documented symptomatic AF > 30 seconds at 18 months after one procedure on or off AAM
time frame: 18 months
measure: Freedom from documented symptomatic atrial arrhythmia > 30 seconds after one procedure on or off AAM
time frame: 18 months
measure: Each of the above success measures stratified by CHA2DS2-VASc score
time frame: 18 months
measure: Incidence of peri-procedural complications including stroke, PV stenosis, cardiac perforation, esophageal injury, phrenic nerve palsy, and death
time frame: 18 months
measure: Procedure duration
time frame: 18 months
measure: Fluoroscopy time (dose)
time frame: 18 months
measure: Radiofrequency time
time frame: 18 months
measure: Number of repeat procedures
time frame: 18 months
measure: Effect of each strategy on AF cycle length changes and AF termination
time frame: 18 months
measure: Correlation of acute AF termination on long-term procedural outcome
time frame: 18 months
measure: Quality of life measurements during follow-up using AFEQT questionnaire
time frame: 6-12-18 months
description: AFEQT questionnaires will be used at baseline, 6, 12 and 18 months
measure: Quality of life measurements during follow-up using SF36 questionnaires
time frame: 6-12-18 months
description: SF36 questionnaires will be used at baseline, 6, 12 and 18 months
measure: Change in AF burden post-ablation procedure (% of time in AF)
time frame: 18 months
arm group label: PV antral isolation alone (PVAI)
arm group type: Active Comparator
description: PV antral isolation alone (PVAI)
arm group label: PV antral isolation plus ablation of drivers
arm group type: Active Comparator
description: PV antral isolation plus ablation of drivers (PVAI+drivers)
arm group label: PV antral isolation plus isolation of posterior wall
arm group type: Active Comparator
description: PV antral isolation plus isolation of LA posterior wall (PVAI+Box)
intervention type: Procedure
intervention name: Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)
description: Standard PVI
arm group label: PV antral isolation alone (PVAI)
intervention type: Procedure
intervention name: Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)
description: Standard PVI + Ablation of drivers in LA and RA
arm group label: PV antral isolation plus ablation of drivers
intervention type: Procedure
intervention name: Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)
description: Standard PVI + Electrical isolation of the posterior wall of the left atrium
arm group label: PV antral isolation plus isolation of posterior wall
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Atul Verma, Dr.
role: Principal Investigator
affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
last name: Laurent Macle, Dr.
role: Principal Investigator
affiliation: Montreal Heart Institute
last name: Mary Morello
phone: 514-376-3330
phone ext: 6279
email: mary.morello@icm-mhi.org
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: Australia
country: Austria
country: Belgium
country: Canada
country: France
responsible party type: Principal Investigator
investigator affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
investigator full name: Atul Verma
investigator title: Cardiologist electrophysiologist
mesh term: Atrial Fibrillation
sharing ipd: No